Target intelligence / Profile preview

ADP-ribosylserine hydrolase (ARH3)

Target
ARH3
Molecular classification
Enzyme, ADP-ribosylglycohydrolase, Hydrolase
01

Overview

ADP-ribosylserine hydrolase (ARH3) is an enzyme of the ADP-ribosylglycohydrolase family, specializing in the removal of ADP-ribose modifications from serine residues on proteins, primarily in the context of DNA damage response. It hydrolyzes the alpha-O-linkage at the anomeric C1'' position of ADP-ribose in proteins, free poly(ADP-ribose), and O-acetyl-ADP-D-ribose, but does not act on ADP-ribosylation at arginine, cysteine, diphthamide, or asparagine. The main physiological roles include safeguarding cells from poly(ADP-ribose)-induced cell death (parthanatos), supporting DNA repair, and contributing to genomic stability. Its function is distinct from related hydrolases such as ARH1 or PARG in substrate specificity and activity. Dysfunction of ARH3 has been implicated in neurodegenerative pathology due to accumulation of toxic ADP-ribose polymers, emphasizing its therapeutic potential and highlighting safety concerns for direct inhibition.

Other names
ADPRSADPRHL2ADP-ribosylhydrolase ARH3ADP-ribosylhydrolase 3ADP-ribose glycohydrolase ARH3O-acetyl-ADP-ribose deacetylase ARH3Poly(ADP-ribose) glycohydrolase ARH3[Protein ADP-ribosylarginine] hydrolase-like protein 2[Protein ADP-ribosylserine] hydrolaseADP-ribosylarginine hydrolase like 2FLJ20446CONDSIAS
02

Mechanism of action

For potential inhibitors—block enzymatic hydrolysis of ADP-ribosyl-serine; interfere with removal of ADP-ribose modifications, modulating DNA repair and programmed cell death.

03

Biological functions

DNA damage responseRemoval of mono-ADP-ribose from serine residuesCell death modulation (specifically parthanatos)Degradation of poly(ADP-ribose)Chromatin dynamics
04

Disease associations

Neurodegenerative diseases (due to cell death via parthanatos)Genomic stability disordersPotential roles in inflammation
05

Safety considerations

Potential for unwanted cell death if the enzyme is inhibited, due to accumulation of toxic poly(ADP-ribose) and exacerbation of parthanatosGenomic instability if DNA repair is impaired
06

Interacting drugs

None currently well-established or in clinical use directly targeting ARH3; most drug development has focused on the related PARP family. Small molecules that inhibit ADP-ribose hydrolases, including ARH3, are under investigation but are not yet clinically available.
07

Biomarkers

Elevated poly(ADP-ribose) levels in cellsaccumulation of mono-ADP-ribosylation at serine, especially on histones in knockout models

Beyond the preview

Go deeper on ADP-ribosylserine hydrolase (ARH3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADP-ribosylserine hydrolase (ARH3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call